Abstract TP279: Effect of Pre-Treatment with Statins on Ischemic Stroke Severity: Does the Doses Matter?
OBJECTIVE: To examine the effect of pre-treatment with statins, at high (80 mg) and non-high (<80 mg) doses, on ischemic stroke (IS) severity in clinical practice.
METHODS: prospective study of IS admissions to our Stroke Unit during a 3-year period (2008-2010). Demographic data, vascular risk factors, previous treatments (statins, ACE inhibitors, ARB, antithrombotic drugs), stroke severity (NIHSS), stroke subtype, in-hospital complications, length of stay and functional status at discharge (mRS) were collected. Mild stroke severity was defined as NIHSS <=5 on admission. Good outcome was defined as mRS <= 2 at discharge. Multivariable regression models and matched propensity score analyses were used to quantify the association of statins pretreatment, at high and non-high doses, with a mild stroke severity.
RESULTS: Of 969 IS patients, 23% were using non-high doses and 4.1% high doses of statins before the stroke event. Statins were associated with lower NIHSS scores on admission (median [IQR], 4  for non-statins patients; 4  for non-high doses of statins and 2  for high doses of statins; p=0.010). The frequency of mild stroke on admission was higher in the statin groups (57.9% for non-statins, 63.2% for non-high doses of statins and 77.5% for high doses of statins, p=0.026). High doses of statins were related with favourable outcomes at discharge, although this was not statistically significant (66.6% for non-statins group, 64.7% for non-high doses of statins and 75% for high doses of statins, p=0.443). After multivariable adjustment, pretreatment with statins was associated with higher odds of mild stroke severity and this effect was greater at high doses (OR=1.637, 95% CI 1.156-2.319 for the non-high doses and OR=3.297, 95% CI 1.480-7.345, for the high doses of statins).
CONCLUSION: Petreatment with statins is associated with lower stroke severity and this effect could be greater at higher doses.
- © 2012 by American Heart Association, Inc.